Endocrinological late complications after hematopoietic SCT in children.
about
Radiosensitive severe combined immunodeficiency disease.Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transplantation in Fanconi anemia patients.Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor.How I treat late effects in adults after allogeneic stem cell transplantation.Health behaviors and cancer screening practices in long-term survivors of hematopoietic cell transplantation (HCT): a report from the BMT Survivor Study.Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS).Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up.Female long-term survivors after allogeneic hematopoietic stem cell transplantation: evaluation and management.Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioningPoor growth, thyroid dysfunction and vitamin D deficiency remain prevalent despite reduced intensity chemotherapy for hematopoietic stem cell transplantation in children and young adultsEndocrine Disorders in Childhood Cancer Survivors Treated with Haemopoietic Stem Cell TransplantationLate thyroid complications in survivors of childhood acute leukemia. An L.E.A. study.Late complications after hematopoietic stem cell transplantation.Hematopoietic stem cell transplantation for curing children with severe autoimmune diseases: is this a valid option?Hematopoietic stem cell transplantation in children with autoimmune connective tissue diseases.A review of late complications of allogeneic hematopoietic stem cell transplantations.Adverse health events and late mortality after pediatric allogeneic hematopoietic SCT-two decades of longitudinal follow-up.Gonadal function and fertility after stem cell transplantation in childhood: comparison of a reduced intensity conditioning regimen containing melphalan with a myeloablative regimen containing busulfan.Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.Self-reported quality of life in long-term survivors of childhood lymphoblastic malignancy treated with hematopoietic stem cell transplantation versus conventional therapy.Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study.Fetal RHD genotyping after bone marrow transplantation.Metabolic syndrome and endocrine dysfunctions after HSCT in children.Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells.Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients
P2860
Q34095701-D05F1382-0718-4D92-9C6F-3CB630179A64Q34166608-919D0F33-FA31-4824-A2F6-924EE32DB71BQ34451605-3BC6B45F-5584-479E-ADC2-C7912CAE1F9DQ34707208-4C5C416D-4E21-4581-91C7-96A3F778F4D5Q35100332-C275F8AC-414C-4DBB-A01E-323B8BAF7B10Q35153809-955813D5-DE1C-4852-B36D-1CB5E6184BA6Q35184667-652D4BE3-D3AD-4C34-AFA6-30D064EA8156Q35671371-6580583D-8B24-4252-92EA-98D6AF22E3B7Q35930597-E39A5820-9E89-4976-A7CA-A23C46FF04CAQ37072004-9BBDA3E0-4A85-4E1F-ADA9-5A2DC50B52FAQ37081520-9A32F5AA-1D3C-4D10-80E8-3C676705528BQ37237908-70C88058-F69F-4B44-BE3E-53B5DBD2C197Q37810122-A0C1E55D-19FA-455E-BD3B-F9D552A905F8Q38004048-795E3F6F-9CCE-4B5B-920B-CAB9874B114DQ38194074-D4E0A382-D0C4-47D0-A4D9-E9C406DCA217Q40115697-0EE2B77B-AF4F-4E61-A0CF-D9DAD346D7BCQ41179462-FEBC8C00-8681-4D89-86C3-CAA5ED3EB14AQ41231320-0D72C3A8-BDCC-4B9E-ADA0-EF3784F164CCQ41643112-D81B184E-BE62-4220-88C5-E40A5FF2CEA4Q44082330-EE838046-176C-45CF-974E-5B51BD4A3965Q45244264-E4F19D3B-ED96-414E-9532-538000C3075DQ48085574-2D4AA70F-7381-4A2E-9805-F0D76228830DQ50893118-97206C32-3E47-41D1-9D40-14DB63EEEAD8Q51298267-73394EE8-27FF-4FE8-B572-71B7B617F0DAQ53343875-BE9AB985-D92B-4F5A-90A2-D1EFA414DD3BQ53941832-A29D1827-E0E6-4C5E-BC25-4DFFB655DA62Q58789022-43577792-1597-49C9-BE8E-97BDBAEA67AB
P2860
Endocrinological late complications after hematopoietic SCT in children.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Endocrinological late complications after hematopoietic SCT in children.
@en
Endocrinological late complications after hematopoietic SCT in children.
@nl
type
label
Endocrinological late complications after hematopoietic SCT in children.
@en
Endocrinological late complications after hematopoietic SCT in children.
@nl
prefLabel
Endocrinological late complications after hematopoietic SCT in children.
@en
Endocrinological late complications after hematopoietic SCT in children.
@nl
P2093
P2860
P356
P1476
Endocrinological late complications after hematopoietic SCT in children.
@en
P2093
A N Békássy
A Tichelli
EBMT Paediatric and Late Effects Working Parties
P2860
P2888
P356
10.1038/BMT.2008.54
P407
P478
41 Suppl 2
P577
2008-06-01T00:00:00Z